Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death
| Autor: | Mónica Ballesteros, Eduard Ródenas, Dimelza Osorio, Josep Ramon Marsal, Lidia García-Pérez, Ivo Roca-Luque, Aida Ribera, Gerard Oristrell, Roxana Escalona, Ignacio Ferreira-González, Mireia Espallargues, Emmanuel Giménez, Yassin Belahnech, Nuria Lozano Rivas |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Medical treatment Heart disease Cost effectiveness business.industry Cost-Benefit Analysis General Medicine Disease 030204 cardiovascular system & hematology medicine.disease State Medicine Defibrillators Implantable Quality-adjusted life year Sudden cardiac death Primary Prevention Clinical trial 03 medical and health sciences Death Sudden Cardiac 0302 clinical medicine Internal medicine Primary prevention medicine Cardiology Humans business |
| Zdroj: | Revista Española de Cardiología (English Edition). 75:12-21 |
| ISSN: | 1885-5857 |
| DOI: | 10.1016/j.rec.2021.05.004 |
| Popis: | Introduction and objectives Implantable cardioverter-defibrillators (ICD) are a cost-effective alternative for secondary prevention of sudden cardiac death, but their efficiency in primary prevention, especially among patients with nonischemic heart disease, is still uncertain. Methods We performed a cost-effectiveness analysis of ICD plus conventional medical treatment (CMT) vs CMT for primary prevention of cardiac arrhythmias from the perspective of the national health service. We simulated the course of the disease by using Markov models in patients with ischemic and nonischemic heart disease. The parameters of the model were based on the results obtained from a meta-analysis of clinical trials published between 1996 and 2018 comparing ICD plus CMT vs CMT, the safety results of the DANISH trial, and analysis of real-world clinical practice in a tertiary hospital. Results We estimated that ICD reduced the likelihood of all-cause death in patients with ischemic heart disease (HR, 0.70; 95%CI, 0.58-0.85) and in those with nonischemic heart disease (HR, 0.79; 95%CI, 0.66–0.96). The incremental cost-effectiveness ratio (ICER) estimated with probabilistic analysis was €19 171/quality adjusted life year (QALY) in patients with ischemic heart disease and €31 084/QALY in those with nonischemic dilated myocardiopathy overall and €23 230/QALY in patients younger than 68 years. Conclusions The efficiency of single-lead ICD systems has improved in the last decade, and these devices are cost-effective in patients with ischemic and nonischemic left ventricular dysfunction younger than 68 years, assuming willingness to pay as €25 000/QALY. For older nonischemic patients, the ICER was around €30 000/QALY. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect